Q32 Bio Inc. — Director's Dealing 2020

Jul 21, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2020-07-21

Reporting Person: Poulton Jeffrey V. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-21	Option (Right to Buy)	$16.48	A	36000	Acquired	2030-07-20	Common Stock (36000)	Direct

Footnotes

F1: The option vests and becomes exercisable in three substantially equal annual installments following the date of grant, subject to the Non-Employee Director continuing service on the Board as a Non-Employee Director through each such vesting date.